First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways in autoimmune and inflammatory diseases, said members of its executive team will participate in three investor conferences in September 2026. The company is scheduled for a fireside chat and one-on-one meetings at the 21st Annual Wells Fargo Healthcare Conference in Boston on Sept. 9 at 9:30 a.m. Eastern Time, one-on-one meetings at Citi’s 2026 Biopharma Back to School Conference in New York City on Sept. 10, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on Sept. 16. A live webcast of the Wells Fargo fireside chat will stream from the investor section of First Tracks’ website, with a replay available for at least 30 days. The company’s pipeline includes ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator.